Patterns of Pain Scores, Health Care Use in Adolescents With Sickle Cell Disease
Investigators assessed the prevalence of neuropathic pain in adolescents with sickle cell disease.
Investigators assessed the prevalence of neuropathic pain in adolescents with sickle cell disease.
In this study, the researchers tested whether sevuparin could shorten vaso-occlusive crisis duration in hospitalized patients with sickle cell disease.
The objective of this study was to assess the efficacy and safety of N-acetylcysteine in the treatment of any chronic pain condition in adults.
L-Glutamine oral treatment with or without hydroxyurea reduces pain crises better than placebo in individuals with sickle cell disease.
In adults with sickle cell disease, higher daily opioid use may be associated with poorer health-related quality of life.
Olinciguat is a soluble guanylate cyclase stimulator currently in Phase 2 development.
In patients with sickle cell disease, review of intermittent pain diaries using a single random day per week or a single week per month was shown to be comparable to review of 5 months’ worth of pain diaries.
The FDA has approved Endari to reduce acute complications of sickle cell disease in patients aged ≥5 years.
A new evidence-based classification system for chronic sickle cell disease pain was recently published.
Crizanlizumab therapy resulted in a significantly lower rate of sickle cell-related pain crises.